Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study-Reference-Cited by-同舟云学术

Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study

Published:2021-02-14 Issue:4 Volume:37 Page:665-674
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Patel Charmi¹,Emond Bruno²,Morrison Laura²,Lafeuille Marie-Hélène²,Lefebvre Patrick²,Lin Dee¹,Kim Edward¹,Joshi Kruti¹

Affiliation:

1. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

2. Analysis Group, Inc., Montréal, QC, Canada

Funder

Janssen Scientific Affairs, LLC

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2021.1882977

Reference29 articles.

1. Schizophrenia

2. Work Group on Schizophrenia. 2010. Practice guideline for the treatment of patients with schizophrenia – second edition [cited 2019 Nov 27]. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia.pdf.

3. National Institute of Mental Health. Schizophrenia [cited 2019 Nov 28]. Available from: https://www.nimh.nih.gov/health/statistics/schizophrenia.shtml.

4. Predictors of Relapse Following Response From a First Episode of Schizophrenia or Schizoaffective Disorder

5. The nature of relapse in schizophrenia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of the real-world effectiveness and economic and humanistic outcomes of selected oral antipsychotics among patients with schizophrenia in the United States: Updating the evidence and gaps;Journal of Managed Care & Specialty Pharmacy;2024-02-03

2. Post Hospitalization Clinical Quality Outcomes Among US Patients with Schizophrenia Treated with a Long-Acting Injectable or Switched to a New Oral Antipsychotic: A Retrospective Cohort Study;Drugs - Real World Outcomes;2023-12-21

3. Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay;Current Medical Research and Opinion;2023-07-28

4. A Cross-Sectional Study of Patient Out-of-Pocket Costs for Antipsychotics Among Medicaid Beneficiaries with Schizophrenia;Drugs - Real World Outcomes;2023-06-08

5. Antipsychotic utilization, healthcare resource use and costs, and quality of care among fee-for-service Medicare beneficiaries with schizophrenia in the United States;Journal of Medical Economics;2023-04-06